tiprankstipranks
Edwards Lifesciences (EW)
NYSE:EW

Edwards Lifesciences (EW) Stock Price & Analysis

1,693 Followers

EW Stock Chart & Stats

Day’s Range$0 - $0
52-Week Range$60.57 - $96.12
Previous Close$90.99
Volume3.49M
Average Volume (3M)2.80M
Market Cap
$54.83B
Enterprise Value$53.95B
Total Cash (Recent Filing)$1.64B
Total Debt (Recent Filing)$694.90M
Price to Earnings (P/E)39.1
Beta1.17
Jul 24, 2024
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)2.33
Shares Outstanding602,600,000
10 Day Avg. Volume2,917,839
30 Day Avg. Volume2,799,100
Standard Deviation0.09
R-Squared0.43
Alpha-0.00271
Financial Highlights & Ratios
Price to Book (P/B)11.03
Price to Sales (P/S)9.12
Price to Cash Flow (P/CF)100.30
P/FCF Ratio172.90
Enterprise Value/Market CapN/A
Enterprise Value/Revenue8.98
Enterprise Value/Gross Profit11.66
Enterprise Value/Ebitda33.06
Forecast
Price Target Upside7.89% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering21

Bulls Say, Bears Say

Bulls Say
Financial FlexibilityCash from the Critical Care sale gives EW flexibility to invest in its core TAVR/TMTT businesses organically and inorganically while earnings benefits from improved growth/margin profile.
Product PerformanceSurvey respondents expect that potential TAVR approval in asymptomatic patients could ultimately lead to an incremental 12% volume growth one year post-approval.
Regulatory ApprovalThe Centers for Medicare & Medicaid Services accepted a formal request to provide a national coverage determination for Edwards' Evoque transcatheter tricuspid valve replacement system.
Bears Say
EarningsThe deal is likely to be EPS dilutive for EW.
Market ShareMarket share erosion expected for EW based on survey respondents.
Sales PerformanceTAVR sales were slightly below consensus estimates.
---

Financials

Annual

Ownership Overview

1.09%23.63%20.73%54.56%
20.73% Other Institutional Investors
54.56% Public Companies and
Individual Investors

Risk Analysis

Main Risk Category
Legal & RegulatoryLitigation, compliance, new legislation, and taxation risks

Website Traffic

Sorry, No Data Available
There is no website visitor data available for this stock.
---

EW FAQ

What was Edwards Lifesciences’s price range in the past 12 months?
Edwards Lifesciences lowest stock price was $60.57 and its highest was $96.12 in the past 12 months.
    What is Edwards Lifesciences’s market cap?
    Currently, no data Available
    When is Edwards Lifesciences’s upcoming earnings report date?
    Edwards Lifesciences’s upcoming earnings report date is Jul 24, 2024 which is in 9 days.
      How were Edwards Lifesciences’s earnings last quarter?
      Edwards Lifesciences released its earnings results on Apr 25, 2024. The company reported $0.66 earnings per share for the quarter, beating the consensus estimate of $0.643 by $0.017.
        Is Edwards Lifesciences overvalued?
        According to Wall Street analysts Edwards Lifesciences’s price is currently Undervalued. Get more investment ideas with TipRanks Premium
          Does Edwards Lifesciences pay dividends?
          Edwards Lifesciences does not currently pay dividends.
          What is Edwards Lifesciences’s EPS estimate?
          Edwards Lifesciences’s EPS estimate is $0.69.
            How many shares outstanding does Edwards Lifesciences have?
            Edwards Lifesciences has 602,600,000 shares outstanding.
              What happened to Edwards Lifesciences’s price movement after its last earnings report?
              Edwards Lifesciences reported an EPS of $0.66 in its last earnings report, beating expectations of $0.643. Following the earnings report the stock price went down -1.795%.
                Which hedge fund is a major shareholder of Edwards Lifesciences?
                Among the largest hedge funds holding Edwards Lifesciences’s share is Fisher Asset Management LLC. It holds Edwards Lifesciences’s shares valued at 729M.
                  ---

                  Company Description

                  Edwards Lifesciences

                  Incorporated in 1958, California-based Edwards Lifesciences Corp. is a medical technology company, which specializes in structural heart disease and critical care and surgical monitoring. It reports in three segments: Transcatheter Aortic Valve Replacements, Transcatheter Mitral and Tricuspid Therapies and Surgical Structural Heart and Critical Care.
                  ---

                  EW Earnings Call

                  Q1 2024
                  0:00 / 0:00
                  ---

                  EW Net sales Breakdown

                  64.61%64.61%16.64%15.46%3.29%
                  64.61% Transcatheter Aortic Valve Replacement
                  16.64% Surgical Structural Heart
                  15.46% Critical Care
                  3.29% Transcatheter Mitral and Tricuspid Therapies
                  tipranks
                  ---

                  EW Stock 12 Month Forecast

                  Average Price Target

                  $98.17
                  ▲(7.89% Upside)
                  {"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"66":"$66","87":"$87","108":"$108","76.5":"$76.5","97.5":"$97.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":107,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n  <span style=\"color:#199ca5\">$107.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":98.17,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n  <span style=\"color:#828080\">$98.17</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":85,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n  <span style=\"color:#912767\">$85.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[66,76.5,87,97.5,108],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Oct<br/>2023","6":"Jan<br/>2024","9":"Apr<br/>2024","12":"Jul<br/>2024","25":"Jul<br/>2025"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,92.32,93.44923076923077,94.57846153846154,95.7076923076923,96.83692307692307,97.96615384615384,99.09538461538462,100.22461538461538,101.35384615384615,102.48307692307692,103.6123076923077,104.74153846153845,105.87076923076923,{"y":107,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,92.32,92.77,93.22,93.67,94.11999999999999,94.57,95.02,95.47,95.92,96.37,96.82,97.27,97.72,{"y":98.17,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,92.32,91.75692307692307,91.19384615384615,90.63076923076923,90.0676923076923,89.50461538461538,88.94153846153846,88.37846153846154,87.81538461538462,87.2523076923077,86.68923076923076,86.12615384615384,85.56307692307692,{"y":85,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":93.38,"date":1689292800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":79.55,"date":1691107200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":76.38,"date":1693526400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":73.7,"date":1696550400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":67.07,"date":1698969600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":68.36,"date":1701388800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":72.85,"date":1704412800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":86.09,"date":1706832000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":85.22,"date":1709251200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":92.7,"date":1712275200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":85.25,"date":1714694400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":88.14,"date":1717718400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":92.32,"date":1720137600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
                  Similar Stocks
                  Company
                  Price & Change
                  Follow
                  Boston Scientific
                  Medtronic
                  Integra Lifesciences
                  Stryker

                  Best Analysts Covering EW

                  1 Year
                  Matt MiksicBarclays
                  1 Year Success Rate
                  24/31 ratings generated profit
                  77%
                  1 Year Average Return
                  +14.26%
                  reiterated a buy rating last month
                  Copying Matt Miksic's trades and holding each position for 1 Year would result in 77.42% of your transactions generating a profit, with an average return of +14.26% per trade.
                  Popular Stocks
                  ---
                  What's Included in PREMIUM?
                  Make informed decisions based on Top Analysts' activity
                  Know what industry insiders are buying
                  Get actionable alerts from top Wall Street Analysts
                  Find out before anyone else which stock is going to shoot up
                  Get powerful stock screeners & detailed portfolio analysis